Key Takeaways
- Durable, drug-free joint management. In an international multicentre prospective study, 82.5% of horses were free of lameness 24 months after a single injection.
- The honest limitations are permanence, the injection risk inherent to any intra-articular procedure, and slower onset than corticosteroids.
- Adverse events are uncommon. In the largest published equine dataset, they were recorded in 0.13% of 2,312 injections across 701 Thoroughbred racehorses over six years, none of them directly product related.
- The evidence is compelling albeit weighted towards observational and retrospective work, with manufacturer involvement disclosed in several studies.
- Best used as a considered choice for the right joint and the right case, and early in the osteoarthritis process.
Introduction
The useful question about 2.5% iPAAG is no longer whether it works. It is where it earns its place in your treatment hierarchy, and what you accept in exchange when you choose it.
2.5% injectable polyacrylamide hydrogel is a drug-free, biocompatible intra-articular hydrogel that integrates into the synovial membrane and acts mechanically rather than solely pharmacologically. The mechanism is covered in our mechanism explainer.
Among 160 equine practitioners surveyed in 2025, the median satisfaction score for intra-articular polyacrylamide gel was 8 out of 10. That is an adoption signal, what follows is the ledger: benefits, risks, evidence quality and clinical fit.
What are the clinical benefits of 2.5% iPAAG?
The principal benefit of 2.5% iPAAG is durable, joint management delivered through a mechanical mode of action targeted at the synovial membrane. In an international multicentre prospective study of 43 horses with osteoarthritis, 82.5% remained free of lameness 24 months after a single injection (Tnibar et al., 2015).
Durability. Real-world data supports that signal. In a six-year retrospective analysis of 701 Thoroughbred racehorses, the mean interval to retreatment of the same joint was approximately 234 days, and treated horses returned to racing a mean of roughly 40 days after treatment (de Clifford et al., 2025). For a horse in work, that changes the treatment calendar, not just the treatment.
Drug-free and repeatable. There is no active pharmaceutical, so there is no mechanistic route to glucocorticoid-mediated insulin dysregulation. That is a statement about the absence of one specific pathway, not a blanket safety claim in metabolic patients. Manufacturer guidance supports treating multiple joints concurrently and repeating doses when clinically indicated, typically at six to twelve month intervals.
Comparative efficacy. In a double-blinded, positive-control study of middle carpal joint lameness in racing Thoroughbreds, 83.3% of iPAAG-treated horses had resolved lameness at six weeks, against 27.3% for triamcinolone acetonide and 40% for sodium hyaluronate (de Clifford et al., 2021). An earlier controlled trial reported soundness in 55%, 65% and 75% of treated horses at one, three and six months, against 15%, 40% and 35% for the same comparator classes (Tnibar et al., 2014). Both populations are specific, and neither generalises automatically to every joint or discipline.
A preclinical joint-protection signal, and a short-acting option alongside. In the Colorado State University osteochondral fragment model, treated joints showed improved lameness and effusion scores and significantly better cartilage scores than controls at day 70 (Contino et al., 2025). That is one preclinical model in induced disease, so it supports a disease-modifying hypothesis. Where a faster effect is also wanted, concurrent injection with betamethasone esters was well tolerated in the metacarpophalangeal joints of 10 healthy horses, with no adverse events recorded (Whitaker et al., 2025), though that study assessed tolerability in normal joints rather than efficacy in diseased ones.
What are the considerations and limitations of 2.5% iPAAG?
The risks of 2.5% iPAAG are low but real, and they fall into four categories: procedure-inherent, product-specific, clinical-fit and evidence-related. In the largest published equine dataset, adverse events were recorded in 0.13% of 2,312 injections administered to 701 Thoroughbred racehorses over six years (de Clifford et al., 2025).
| Risk or limitation | Nature | Mitigation |
| Iatrogenic synovial sepsis | Inherent to any intra-articular injection, not specific to iPAAG | Strict asepsis; clinician performs own skin preparation; syringe and needle handling critical to maintain sterility. |
| Long-lasting | Fully biocompatible. Integrated by day 14 and cannot be retrieved | Accurate diagnosis, localisation and injection technique critical; deliberate joint and case selection. |
| Low-level immune response after injection (<1:2,500) | Macrophage-driven and expected, with no fibrosis, granuloma or mineralisation on histology | Reduce exercise demand immediately after treatment; distinguish non-septic reaction from sepsis. Consider using systemic NSAID’s or local Mepivicaine. |
| Slower onset than corticosteroids | Not an acute anti-inflammatory. Effect builds over 10 to 14 days | Combine with a short-acting agent where rapid effect is needed. |
| No reversal of structural bony change | Acts on synovium and joint capsule, not on bony remodelling | Set expectations; use within a wider management plan |
| Cost and timing | Higher unit cost than some other therapies; integration window and durability sits inside the rehab programme | Weigh against reduced treatment frequency and long term joint health; treat earlier in the programme |
Procedure-inherent risk. Every intra-articular injection carries a risk of iatrogenic synovial sepsis. Published equine figures are low: 13 septic joints in 16,624 injections, or one case per 1,279, in Thoroughbred racehorses (Steel et al., 2013), and 4 in 9,456 intrasynovial medications in ambulatory practice (Smith et al., 2018). Pooled across three studies and 345,840 injections, prevalence was 0.02% (Braid, 2019). One caveat matters here: the 0.13% iPAAG figure counts all recorded adverse events and none of these were sepsis or product related, while these studies count confirmed sepsis only. They measure different things and should not be read as a head-to-head comparison.
Permanence. This is a consideration that most deserves attention. Scanning electron microscopy shows the gel particles are integrated as a three-dimensional scaffold, with no free gel remaining in the joint cavity by day 14 (Lowe et al., 2024). They cannot be removed, lavaged out or reversed. A permanent implant places more weight on the diagnostic work that precedes it but permanence should also be considered in terms of bio-stability. 2.5% iPAAG does not remain as a discrete foreign body. It integrates into the synovial membrane over time with no migration, no encapsulation, and no mechanical interference with cartilage or surrounding tissues.
Macrophage response and non-septic reactions. Injection into normal equine joints produced more macrophage infiltration, villus hyperplasia and vascularisation than controls, with no fibrosis or mineralisation, but most importantly arthrocentesis cytology remaining within clinically normal ranges across 90 days (Lowe et al., 2024). Note the population: 10 healthy horses and 13 normal joints, not diseased ones. Clinically, what this means is a small number of horses may develop transient pain and oedema at the treatment site. Sepsis must be excluded first, because the treatment strategies diverge. Once it is excluded, further intra-articular intervention is contraindicated and may inadvertently worsen the reaction.
Onset and the integration window. Practice varies. In practitioner surveys, most respondents prescribe box rest on days one to three, controlled exercise from day four through week two, and full exercise from week two onwards. Manufacturer guidance is ideally to treat during periods of reduced exercise demand, or earlier in the programme than would be usual for shorter-acting alternatives.
Competition and racing. 2.5% iPAAG contains no active pharmaceutical, and Arthramid’s New Zealand and Australian materials state no competition withhold time. That is not the same as unrestricted. FEI Veterinary Regulations prohibit intra-articular and intrasynovial administration of any medication during FEI Events, and racing jurisdictions set their own rules on injections before a start. Confirm current requirements with the relevant regulatory body before treating a horse in competition or in a racing preparation.
Benefits and considerations at a glance
| Consideration | What the evidence supports | What it means to you |
| Duration | 82.5% lameness-free at 24 months after one injection; mean retreatment interval about 234 days in racing practice | Effect builds over 10 to 14 days |
| Mode of action | Mechanical, synovium-targeted, no active pharmaceutical | No acute anti-inflammatory effect |
| Comparative efficacy | 83.3% resolution at six weeks against 27.3% and 40% for the comparators studied | Data comes from specific joints and populations |
| Safety | Adverse events in 0.13% of 2,312 injections; normal cytology to 90 days in healthy joints. | Baseline injection risk still applies |
| Reversibility | Not applicable | Biostable, case selection must be right |
| Repeatability | Repeat and multi-joint treatment supported | Higher unit cost weighed against long term joint health and longer treatment intervals. |
How strong is the evidence for 2.5% iPAAG?
The controlled evidence. The double-blinded, positive-control comparison against triamcinolone acetonide and sodium hyaluronate (de Clifford et al., 2021) is the methodologically strongest equine efficacy study for this product, supported by the earlier controlled trial (Tnibar et al., 2014). On the preclinical side, the Colorado State University osteochondral model and the accompanying synovial transcriptomic work add mechanistic support (Contino et al., 2025; Chow et al., 2026). Both use experimentally induced acute disease, which is not the same as naturally occurring chronic osteoarthritis.
The observational evidence. The 24-month multicentre study (Tnibar et al., 2015) was prospective but small and uncontrolled. The 701-horse retrospective (de Clifford et al., 2025) is the largest safety dataset available and genuinely useful for real-world signal, but retrospective design, absent controls and clinician-directed case selection.
That caveat applies to one of its more striking findings. Catastrophic musculoskeletal injury occurred at 0.199 per 1,000 starts in the treated cohort, against a reported industry figure of 0.52 per 1,000. It is an encouraging signal. It is not evidence of a protective effect, because those horses were selected for treatment by their veterinarians rather than randomised.
The mechanism. The original goat-model work is titled as preliminary observations (Tnibar et al., 2017), and the 2025 review describes the mechanism in those terms (Tnibar, 2025). Recent transcriptomic and biomechanical work is filling that gap (Contino et al, 2025, Chow et al, 2026).
Conflict of interest. Several studies in this body of work are authored by clinicians affiliated with the manufacturer or its distributors, and funding relationships are disclosed. That is normal in veterinary product research and is not disqualifying. It is a reason to weight controlled and independent data more heavily when forming your own view.
The adoption curve. The 2025 survey reported a median satisfaction score of 8 out of 10 across 160 complete responses, with chronic synovitis and osteoarthritis (87.1%) and failure of prior joint treatment (83.6%) as the leading indications (Pluim and Frippiat, 2025). It covered intra-articular polyacrylamide gel as a category rather than a single product, so read it as evidence of how the class is used, not as product-specific outcome data.
Review the controlled clinical evidence and form your own view of the dataset behind this appraisal.
When is 2.5% iPAAG appropriate, and when is it not?
2.5% iPAAG suits considered use in the right joint and the right case: chronic synovitis and osteoarthritis, cases where repeated corticosteroid use is losing effect, and horses where steroid-sparing management is preferred. Where rapid anti-inflammatory effect is the priority, or where the presenting problem is structural (e.g. sub-chondral bone) rather than synovial, consider additional therapies concurrently . The reason sits in the mode of action, which is mechanical with downstream biological effects rather than pharmacological.
Cases that may suit
- Chronic synovitis or osteoarthritis where durable management matters more than speed of onset
- Horses in which repeat corticosteroid medication is delivering diminishing returns
- Cases where steroid-sparing management is clinically or commercially preferred
- Horses that can be treated earlier in the programme, with a reduced-exercise window available
- Multi-joint cases where a repeatable, drug-free option simplifies the plan
Cases that warrant consideration or a additional alternative
- Presentations requiring rapid anti-inflammatory control, unless combined with a short-acting agent
- Advanced structural disease where the limiting factor is bony remodelling rather than synovitis
- Cases without accurate localisation or adequate imaging. A permanent implant is the wrong answer to an uncertain diagnosis
- Horses in a competition or racing preparation where timing has not been checked against current requirements
The corticosteroid trade-off, stated neutrally. Corticosteroids offer speed and reversibility. 2.5% iPAAG offers durability and a drug-free mode of action. Neither is universally better, and the two are not mutually exclusive within a plan. The mechanism-level comparison is covered in our corticosteroid comparison article.
The balanced verdict
2.5% iPAAG has a favourable profile for defined indications: durable, drug-free management of synovitis and osteoarthritis, with a low reported adverse-event rate and controlled data showing it outperforming conventional intra-articular comparators in the joints and populations studied. The honest caveats are permanence, slower onset, and no effect on structural bony change. None of those is a reason to avoid it. All of them are reasons to select the case deliberately, because with a permanent implant the diagnosis carries more weight than the product does.
